In conclusion, among several other markers assessed in multiple tissue compartments, B2M expression in tumor cells exhibited a strong association with immunotherapy outcomes in R/M HNSCC, an effect that was reproduced in an additional, validation cohort. This evidence concerns the gene B2M and neoplasm.